Friday, January 28, 2022 8:33:05 AM
'MI Dendream:In which post of yours have you articulated this thesis in the most comprehensive way?
MI Dendream Thursday, 01/27/22 10:09:53 PM
Re: sentiment_stocks post# 439298 0
Post #
439302
of 439348
I am one of the originators of this thesis. In my thesis, neither investigators, patients nor company knew that placebo was removed. BTW this was my thesis in August of 2015 which I shared with everyone invested as a connection with me.
Evidence to this thesis is the FACT that the final 31-32 patients were only placed on treatment, no randomization to placebo. While this only directly ties to those not yet randomized, the rationale to do this creates a moral and ethical obligation to treat every human being who volunteered their life to the study of a potential therapy. There is an obligation to those patients to first do no harm and to progress with GBM is to die, at least if they stay on placebo, and at that point it is not known whether or not DCVax can rescue a portion of them after progressing, it was only known that it delays death before progression.
MI Dendream Thursday, 01/27/22 10:09:53 PM
Re: sentiment_stocks post# 439298 0
Post #
439302
of 439348
I am one of the originators of this thesis. In my thesis, neither investigators, patients nor company knew that placebo was removed. BTW this was my thesis in August of 2015 which I shared with everyone invested as a connection with me.
Evidence to this thesis is the FACT that the final 31-32 patients were only placed on treatment, no randomization to placebo. While this only directly ties to those not yet randomized, the rationale to do this creates a moral and ethical obligation to treat every human being who volunteered their life to the study of a potential therapy. There is an obligation to those patients to first do no harm and to progress with GBM is to die, at least if they stay on placebo, and at that point it is not known whether or not DCVax can rescue a portion of them after progressing, it was only known that it delays death before progression.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
